References

Pembrolizumab for early triple-negative breast cancer

10.1056/nejmoa1910549 · 2020 · External reference

Event-free survival with pembrolizumab in early triple-negative breast cancer

10.1056/nejmoa2112651 · 2022 · External reference

Overall survival with pembrolizumab in early-stage triple-negative breast cancer

10.1056/nejmoa2409932 · 2024 · External reference

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

10.1038/s41571-019-0218-0 · 2019 · External reference

Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer

10.1016/j.esmorw.2024.100061 · 2024 · External reference

LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

10.1016/j.annonc.2023.10.009 · 2023 · External reference

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

10.1038/s41591-025-03725-4 · 2025 · External reference

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

10.1016/j.annonc.2022.07.1940 · 2022 · External reference

292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): long-term analysis from the GeparNuevo trial

10.1016/j.annonc.2025.08.721 · 2025 · External reference

Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer

10.1158/1557-3265.sabcs24-gs3-05 · 2025 · External reference

Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA/IMpassion030 randomized clinical trial

10.1001/jama.2024.26886 · 2025 · External reference

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

10.1016/j.annonc.2025.08.005 · 2025 · External reference

Abstract LB1-07: exploratory biomarker analysis of the phase 3 KEYNOTE-522 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage TNBC

10.1158/1557-3265.sabcs24-lb1-07 · 2025 · External reference

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

10.1093/annonc/mdz395 · 2019 · External reference

Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers

10.1200/jco.18.01010 · 2019 · External reference

Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy

10.1001/jamaoncol.2024.1917 · 2024 · External reference

Tumor-infiltrating lymphocytes in triple-negative breast cancer

10.1001/jama.2024.3056 · 2024 · External reference

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

10.1016/s1470-2045(17)30904-x · 2018 · External reference

2O Integrating tumor infiltrating lymphocytes and nodal status for risk stratification in patients (pts) with triple-negative breast cancer (TNBC) and pathological complete response (pCR) after neoadjuvant treatment (NAT)

10.1016/j.esmoop.2025.104557 · 2025 · External reference

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

10.1093/annonc/mdv241 · 2015 · External reference

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

10.1016/s1470-2045(21)00589-1 · 2022 · External reference

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

10.1093/annonc/mdy547 · 2019 · External reference

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

10.1093/annonc/mdu450 · 2015 · External reference

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

10.1016/j.semcancer.2017.10.003 · 2018 · External reference

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer

10.1038/s41523-021-00362-1 · 2022 · External reference

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

10.1038/s41523-025-00814-y · 2025 · External reference

Abstract RF3-02: gene expression-based subtyping of early triple-negative breast cancer (TNBC) for prediction of response to neoadjuvant immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze trial

10.1158/1557-3265.sabcs25-rf3-02 · 2026 · External reference